Caplacizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Caplacizumab. Educational only — not medical advice.
Labeled uses
CABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Source: FDA labeling via NIH DailyMed (set 2348f06e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.